GLIONOVA
Glionova AB, a development stage biopharmaceutical company, is engaged in the development of therapies for difficult-to-treat cancers. The company develops GLN-1001, an orally bioavailable small molecule that induces selective cell death in glioblastoma cells without causing harm to normal brain tissue.
GLIONOVA
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.glionova.com
Total Employee:
1+
Status:
Active
Contact:
+46 70 540 6519
Total Funding:
5.7 M USD
Technology used in webpage:
OpenResty Baidu Analytics DNS.COM
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Employees Featured
Founder
Investors List
Novo Holdings
Novo Holdings investment in Series A - Glionova
HealthCap
HealthCap investment in Series A - Glionova
Industrifonden
Industrifonden investment in Series A - Glionova
